We Discover, Register, and Deploy Advanced Medicines.
TadbeerPharma is not an importer. We analyze molecular structures to identify affordable therapeutics, prepare complete AFDA registration dossiers, and deploy newly-registered drugs across Afghanistan's healthcare network.
Our moat is scientific and regulatory — not logistical. By navigating Afghanistan's drug registration pathway for molecules with publicly-available Phase 3 evidence, we introduce medicines that were previously inaccessible, at a fraction of originator prices.
Pipeline Status
Active Dossiers
Across oncology, antivirals & chronic care
The Distinction That Matters
Most pharmaceutical distributors in Afghanistan procure whatever is available on international markets and apply for import permits. We work upstream — identifying molecules with proven efficacy, sourcing GMP-certified manufacturers, and driving the AFDA registration ourselves.
The result: drugs that were previously unregistered in Afghanistan — and therefore unavailable to patients regardless of willingness to pay — become part of the accessible healthcare system.
Molecular Analysis
Computational chemistry meets regulatory strategy
Before a molecule ever reaches an AFDA dossier, it passes through our analysis pipeline — assessing structural equivalence to reference drugs, stability under Afghan climatic conditions, and regulatory data sufficiency for filing.
Bioequivalence Mapping
Computational comparison of generic APIs against reference-listed drugs to establish therapeutic equivalence prior to registration commitment.
API Stability Profiling
Accelerated stability modeling under Afghan storage conditions — extreme temperature ranges, humidity variation — to select optimal formulations.
Off-Patent Candidate Identification
Systematic screening of patent expiry databases to identify molecules where generic registration delivers immediate and material cost reduction within the Afghan healthcare system.
Regulatory Pathway Analysis
Assessment of existing Phase 3 data quality and completeness to determine the fastest viable pathway to AFDA registration approval.
The AFDA Registration Dossier
Afghanistan's Food and Drug Authority requires a complete technical dossier for product registration. We prepare and submit these dossiers in parallel with manufacturing setup — not sequentially. Registration is obtainable; the bottleneck is preparation, and that is what we have solved.
Product Details
RequiredFull product name, qualitative and quantitative composition, dosage form, and strength. Includes proposed indication, route of administration, and shelf-life claim.
Manufacturing Site Details
RequiredCurrent WHO-GMP certificate from the contracted manufacturer. We work with GMP-certified facilities in Bangladesh, India, and Turkey — selected for cost efficiency without compromising quality.
Clinical Data
Publicly AvailablePhase 3 trial data establishing safety and efficacy. For established off-patent molecules, this evidence base exists in published literature and international regulatory submissions — compiled and formatted to AFDA specifications.
Quality Data
RequiredAPI Certificate of Analysis (CoA) from the manufacturer, along with proposed finished product specifications covering identity, assay, dissolution, and impurity profiles.
Afghan Language Labelling
RequiredFull product label in Dari/Pashto meeting AFDA labelling guidelines — including product name, active ingredient, dosage instructions, storage conditions, and batch/expiry information.
Registration Begins at Molecule Clearance — Not at Contract Signing
Dossier preparation commences the moment a molecule clears our analysis pipeline, running concurrently with manufacturer selection. This structural discipline — parallel workstreams rather than sequential dependency — compresses time-to-market by months and is the operational difference between a pipeline and a registered product.
Active Pipeline
Molecules currently moving through our discovery-to-registration process
Pipeline represents indicative candidates under analysis. Registration timelines subject to AFDA review processes.
Interested in Our Drug Registration Pipeline?
We engage healthcare ministries, international NGOs, and hospital procurement teams seeking access to advanced therapeutics at sustainable price points. Our registration pipeline is open to co-investment and strategic partnership.